Biotechnology
Commented by Carsten Mainitz on March 3rd, 2021 | 07:34 CET
Evotec, Cardiol Therapeutics, MorphoSys - Watch out: Great upside potential here in the short term
In the pandemic, investors have learned that small biotech companies, some still with a start-up character, can be worth billions overnight. BioNTech and CureVac are familiar names from the press. Both are linked by the Corona drug and the fact that they are headquartered in Germany. Two other German companies, Evotec and MorphoSys, have written a good growth story on the stock exchange in recent years: small becomes big! Small is also still the Canadian Cardiol Therapeutics. With the announced dual listing on the US technology exchange Nasdaq, a valuation boost could be imminent.
Read
Commented by André Will-Laudien on February 17th, 2021 | 10:39 CET
Cardiol Therapeutics, Formycon, Teva Pharmaceuticals: COVID in focus!
According to recent statistics from the WHO, nowhere is research currently more intense than in the area of viral diseases. At least 248 vaccine projects have been initiated against COVID-19 since January 2020, but only the research projects have already been reported. But of course, we humans do not only fall ill from flu viruses and their dangerous mutants, but the permanent change in our lives alone intensifies diseases that arise from lack of exercise and contact and sometimes cause worse consequences than a flu-like effect. Everyone is currently looking to hopeful vaccine solutions, but several biotech and pharmaceutical companies can still make us healthier with new developments.
Read
Commented by Nico Popp on October 16th, 2020 | 12:19 CEST
CureVac, BioNTech, Valeo Pharma: Where is there still potential?
The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac recently started its phase study IIa in Peru and Panama. Around 700 people are taking part in it. The study aims to find suitable dosages for the vaccine. To this end, test persons are vaccinated twice within 28 days. Other competitors, such as BioNTech, are already testing their vaccine on more volunteers. BioNTech recently started its phase III study in South Africa and is testing the vaccine on more than 40,000 people worldwide.
Read
Commented by Mario Hose on March 19th, 2020 | 11:25 CET
BioNTech, Gilead, Memphasys - modern science and COVID and IVF
People around the world are worried about the extent of the consequences associated with the spread of the corona virus COVID-19, and politicians and the economy are called upon to deal with the situation appropriately so that the loss of life and financial damage to the citizens can be kept to a minimum. Medical experts are now working intensively to ensure that active substances for prevention and therapy are tested and made ready for the market.
Read